Edaravone Oral Suspension (Radicava)

Key Messages

• CADTH recommends that Radicava should be reimbursed by public drug plans for the treatment of patients with amyotrophic lateral sclerosis (ALS), if certain conditions are met.
• Radicava oral suspension should only be covered to treat patients with ALS provided that it is covered for a similar patient population and in a similar way to the IV formulation of Radicava for the treatment of adult patients with ALS.
• Radicava oral suspension should only be reimbursed if prescribed in a similar manner as the IV formulation of Radicava is prescribed, and that the cost of Radicava oral suspension does not exceed the drug program cost of IV formulation of Radicava.